Hypomagnesemia — Mechanisms and Treatment

Electrolyte Disordersmedium

A 55-year-old woman with metastatic colorectal cancer is treated with cetuximab (anti-EGFR monoclonal antibody). After 6 cycles, she presents with muscle cramps, tremors, and ECG changes (prolonged QTc, wide QRS). Labs: magnesium 0.5 mg/dL (normal 1.6–2.6), potassium 2.8 mEq/L, calcium 7.8 mg/dL. What is the mechanism of hypomagnesemia in this patient and the MOST appropriate management?

  1. A.Nutritional deficiency from chemotherapy-induced anorexia; oral magnesium supplementation
  2. B.Cetuximab blocks EGFR on TRPM6 channel → renal magnesium wasting; IV magnesium sulfateCorrect
  3. C.Cisplatin nephrotoxicity causing tubular dysfunction; stop cetuximab and start IV calcium gluconate
  4. D.Redistribution hypomagnesemia from alkalosis; correct pH with ammonium chloride

Explanation

Cetuximab (and panitumumab), anti-EGFR monoclonal antibodies, cause renal magnesium wasting by inhibiting EGFR-dependent signaling that regulates TRPM6 (transient receptor potential melastatin 6) channel expression/activity in the distal tubule. TRPM6 is the primary channel for active Mg2+ reabsorption in the DCT. EGFR signaling is required for TRPM6 channel trafficking to the apical membrane. Without EGFR → TRPM6 internalized → reduced Mg2+ reabsorption → renal Mg2+ wasting (high urine Mg2+ despite low serum Mg2+). Hypomagnesemia can be severe (requiring IV replacement) and may persist for months after cetuximab cessation. Consequences of hypomagnesemia: (1) Refractory hypokalemia (intracellular Mg2+ normally inhibits the ROMK channel; low Mg2+ removes this inhibition, so distal K+ secretion increases and drives renal K+ wasting; K+ cannot be corrected without correcting Mg2+); (2) Refractory hypocalcemia (Mg2+ required for PTH secretion); (3) Cardiac arrhythmias (QTc prolongation, torsades de pointes). Management: IV magnesium sulfate (preferred when symptomatic or severe); concurrent K+ and Ca2+ replacement. Oral Mg2+ supplements have poor GI absorption (diarrhea), insufficient for severe cases. Monitor Mg2+ throughout anti-EGFR therapy.

Why each option

A.
Nutritional hypomagnesemia would be from low intake; here the mechanism is renal wasting from EGFR blockade; IV replacement needed for severity of 0.5 mg/dL.
B.
Correct. Cetuximab → EGFR inhibition → TRPM6 downregulation in DCT → renal Mg2+ wasting; IV MgSO4 for symptomatic severe hypomagnesemia.
C.
Cisplatin causes tubular wasting (proximal tubule damage) but this patient is on cetuximab, not cisplatin; EGFR mechanism is distinct.
D.
Redistribution hypomagnesemia is rare; alkalosis shifts Mg2+ into cells but does not explain severe symptomatic depletion.

Reference: Dimke H, NEJM 2010; Schrag D, J Natl Cancer Inst 2005 (cetuximab hypomagnesemia); Cunha C, Clin Chem Lab Med 2013

This is one of 1,100 questions in the MedBoardSA nephrology bank, with timed test mode, tutor mode, and progress tracking by topic.

Practise the full bank

More Electrolyte Disorders questions

Browse other topics